Novo and Martin Marietta contributed to the biocement producer’s latest round, which was led by 2150 and which will fund hiring and technology development.
US-headquartered biological construction material developer Biomason secured $65m in series C funding yesterday from investors including pharmaceutical firm Novo and building materials provider Martin Marietta.
2150 led the round, which also featured venture capital firm Celesta Capital and energy and commodities trading firm Hartree Partners.
Founded in 2012, Biomason provides cement created with materials grown from microorganisms that is known as biocement and which is intended to gradually substitute for its traditional counterpart.
The company claims its products can help…
